SOUTH SAN FRANCISCO, California, June 18 /PRNewswire/ -- Synosia Therapeutics today announced that it has appointed Michael S. Eison, Ph.D., as the company’s new vice president of regulatory affairs, effective immediately.
Dr. Eison is an experienced drug developer and a seasoned veteran of regulatory affairs. He spent the first 15 years of his career in central nervous system (CNS) drug discovery/science management and the subsequent 11 years in regulatory affairs, formulating regulatory strategies that anticipate the needs of the marketplace as well as those of worldwide health authorities.
“Michael Eison brings a depth of experience in CNS that enhances our already solid capabilities in that area,” said Synosia Chief Executive Officer and President Ian Massey, “and the addition of his regulatory experience certainly improves our ability to successfully navigate the regulatory processes for CNS drug development.”
Most recently, Eison was vice president of research and development for the Palo Alto site of Stiefel Laboratories, but the majority of his career was with the Bristol-Myers Squibb Company. He joined them as a scientist in 1981 and ultimately became the director of CNS drug discovery before changing career direction and becoming a director in regulatory affairs. He joined InterMune in 2002 as senior director regulatory affairs and Connetics in 2005 as vice president of regulatory affairs.
“It’s an exciting time to be joining Synosia, with seven clinically enabled compounds in the pipeline,” said Eison, “yet early enough for regulatory to make important contributions to development strategies that satisfy regulators, meet the needs of patients and advance the business interests of Synosia.”
Eison earned his bachelor’s degree in psychology in 1975 at the State University of New York at Buffalo and was awarded his doctorate in physiological psychology/psychopharmacology from UCLA in 1980.
About Synosia Therapeutics
Synosia Therapeutics is a privately-owned, drug development company, focused on developing new treatments for disorders of the central nervous system. Its leadership team has over 180 years of combined experience in drug development. Synosia has offices in Basel, Switzerland, and is headquartered in South San Francisco, CA. The company was spun out of EuroVentures Inc., a wholly-owned incubator of Versant Ventures, and recently changed its name from Synosis Therapeutics.
Synosia Therapeutics has raised $32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit www.synosia.com
Synosia Therapeutics
CONTACT: Contact Synosia Therapeutics: In Europe: Julie Walters at MediaSpeak, Tel: +44-(0)-1494-753-990, Mobile +44-(0)-775-3626967,julie.walters@mediaspeak.com; In US: Michele Parisi at Media Speak, Tel:+1-925-864-5028, michele.parisi@mediaspeak.com
